Engineered immune cells take on Hard-to-Treat liver cancer in early trial
NCT ID NCT06757881
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment for people with advanced liver cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) designed to target a protein called IL1RAP on cancer cells. Only 3 participants are enrolled, and the main goal is to check safety and side effects, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.